nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—stomach cancer—esophageal cancer	0.426	1	CtDrD
Capecitabine—TYMP—esophageal cancer	0.37	1	CbGaD
Capecitabine—TYMS—Methotrexate—esophageal cancer	0.0895	0.891	CbGbCtD
Capecitabine—CYP2C9—Cisplatin—esophageal cancer	0.0109	0.109	CbGbCtD
Capecitabine—CES1—larynx—esophageal cancer	0.00492	0.238	CbGeAlD
Capecitabine—DPYD—bronchus—esophageal cancer	0.00175	0.0846	CbGeAlD
Capecitabine—Hepatic fibrosis—Methotrexate—esophageal cancer	0.00173	0.0602	CcSEcCtD
Capecitabine—CES1—neck—esophageal cancer	0.00131	0.0631	CbGeAlD
Capecitabine—Venous thrombosis—Carboplatin—esophageal cancer	0.0012	0.0417	CcSEcCtD
Capecitabine—DPYD—lung—esophageal cancer	0.00113	0.0546	CbGeAlD
Capecitabine—TYMP—bronchus—esophageal cancer	0.00101	0.049	CbGeAlD
Capecitabine—TYMP—smooth muscle tissue—esophageal cancer	0.000992	0.048	CbGeAlD
Capecitabine—TYMP—trachea—esophageal cancer	0.00091	0.044	CbGeAlD
Capecitabine—TYMS—bronchus—esophageal cancer	0.000869	0.0421	CbGeAlD
Capecitabine—TYMS—smooth muscle tissue—esophageal cancer	0.000851	0.0411	CbGeAlD
Capecitabine—TYMP—digestive system—esophageal cancer	0.000783	0.0379	CbGeAlD
Capecitabine—DPYD—lymph node—esophageal cancer	0.000772	0.0373	CbGeAlD
Capecitabine—CDA—lymph node—esophageal cancer	0.000743	0.0359	CbGeAlD
Capecitabine—Nail changes—Methotrexate—esophageal cancer	0.000717	0.025	CcSEcCtD
Capecitabine—CES1—digestive system—esophageal cancer	0.000676	0.0327	CbGeAlD
Capecitabine—TYMS—digestive system—esophageal cancer	0.000672	0.0325	CbGeAlD
Capecitabine—Fibrosis—Cisplatin—esophageal cancer	0.000664	0.0231	CcSEcCtD
Capecitabine—TYMP—lung—esophageal cancer	0.000654	0.0316	CbGeAlD
Capecitabine—Gastrointestinal toxicity—Methotrexate—esophageal cancer	0.000634	0.0221	CcSEcCtD
Capecitabine—CES1—lung—esophageal cancer	0.000564	0.0273	CbGeAlD
Capecitabine—TYMS—lung—esophageal cancer	0.000561	0.0271	CbGeAlD
Capecitabine—Phlebitis—Carboplatin—esophageal cancer	0.000545	0.019	CcSEcCtD
Capecitabine—Mood alteration NOS—Methotrexate—esophageal cancer	0.000519	0.0181	CcSEcCtD
Capecitabine—Neurotoxicity—Cisplatin—esophageal cancer	0.000489	0.017	CcSEcCtD
Capecitabine—TYMP—lymph node—esophageal cancer	0.000447	0.0216	CbGeAlD
Capecitabine—Thromboembolic event—Methotrexate—esophageal cancer	0.000387	0.0135	CcSEcCtD
Capecitabine—CES1—lymph node—esophageal cancer	0.000386	0.0187	CbGeAlD
Capecitabine—TYMS—lymph node—esophageal cancer	0.000384	0.0186	CbGeAlD
Capecitabine—Fibrosis—Methotrexate—esophageal cancer	0.000364	0.0127	CcSEcCtD
Capecitabine—Venous thrombosis—Cisplatin—esophageal cancer	0.000351	0.0122	CcSEcCtD
Capecitabine—Febrile neutropenia—Cisplatin—esophageal cancer	0.000315	0.011	CcSEcCtD
Capecitabine—Serum creatinine increased—Cisplatin—esophageal cancer	0.000308	0.0107	CcSEcCtD
Capecitabine—Enteritis—Methotrexate—esophageal cancer	0.000305	0.0106	CcSEcCtD
Capecitabine—CYP2C9—digestive system—esophageal cancer	0.000293	0.0142	CbGeAlD
Capecitabine—Neurotoxicity—Methotrexate—esophageal cancer	0.000268	0.00935	CcSEcCtD
Capecitabine—Rales—Methotrexate—esophageal cancer	0.000254	0.00884	CcSEcCtD
Capecitabine—Pericardial effusion—Methotrexate—esophageal cancer	0.000254	0.00884	CcSEcCtD
Capecitabine—Hepatotoxicity—Cisplatin—esophageal cancer	0.000246	0.00856	CcSEcCtD
Capecitabine—Rhinorrhoea—Cisplatin—esophageal cancer	0.000234	0.00816	CcSEcCtD
Capecitabine—Ageusia—Cisplatin—esophageal cancer	0.000234	0.00816	CcSEcCtD
Capecitabine—Infection—Carboplatin—esophageal cancer	0.000229	0.00799	CcSEcCtD
Capecitabine—Cellulitis—Cisplatin—esophageal cancer	0.000209	0.00727	CcSEcCtD
Capecitabine—Sudden death—Methotrexate—esophageal cancer	0.000203	0.00709	CcSEcCtD
Capecitabine—Ulcer—Cisplatin—esophageal cancer	0.000201	0.00699	CcSEcCtD
Capecitabine—Dysarthria—Cisplatin—esophageal cancer	0.000201	0.00699	CcSEcCtD
Capecitabine—Hearing impaired—Cisplatin—esophageal cancer	0.000199	0.00694	CcSEcCtD
Capecitabine—Pain—Carboplatin—esophageal cancer	0.000197	0.00687	CcSEcCtD
Capecitabine—Hiccups—Cisplatin—esophageal cancer	0.00019	0.00661	CcSEcCtD
Capecitabine—Mucosal inflammation—Methotrexate—esophageal cancer	0.000188	0.00655	CcSEcCtD
Capecitabine—Body temperature increased—Carboplatin—esophageal cancer	0.000182	0.00635	CcSEcCtD
Capecitabine—Skin exfoliation—Cisplatin—esophageal cancer	0.000181	0.00631	CcSEcCtD
Capecitabine—Fluid retention—Cisplatin—esophageal cancer	0.00018	0.00627	CcSEcCtD
Capecitabine—Neuropathy—Cisplatin—esophageal cancer	0.000178	0.0062	CcSEcCtD
Capecitabine—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000175	0.0061	CcSEcCtD
Capecitabine—Febrile neutropenia—Methotrexate—esophageal cancer	0.000173	0.00603	CcSEcCtD
Capecitabine—Deep vein thrombosis—Methotrexate—esophageal cancer	0.000171	0.00596	CcSEcCtD
Capecitabine—Encephalopathy—Methotrexate—esophageal cancer	0.000162	0.00565	CcSEcCtD
Capecitabine—Embolism—Methotrexate—esophageal cancer	0.000162	0.00565	CcSEcCtD
Capecitabine—Aphasia—Methotrexate—esophageal cancer	0.00016	0.00559	CcSEcCtD
Capecitabine—Nail disorder—Methotrexate—esophageal cancer	0.00016	0.00559	CcSEcCtD
Capecitabine—Phlebitis—Cisplatin—esophageal cancer	0.00016	0.00557	CcSEcCtD
Capecitabine—Polyuria—Cisplatin—esophageal cancer	0.000157	0.00546	CcSEcCtD
Capecitabine—Bone marrow depression—Methotrexate—esophageal cancer	0.000154	0.00537	CcSEcCtD
Capecitabine—Deafness—Cisplatin—esophageal cancer	0.000154	0.00536	CcSEcCtD
Capecitabine—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000153	0.00531	CcSEcCtD
Capecitabine—Haematemesis—Methotrexate—esophageal cancer	0.00015	0.00522	CcSEcCtD
Capecitabine—Renal failure acute—Cisplatin—esophageal cancer	0.000149	0.0052	CcSEcCtD
Capecitabine—Amnesia—Cisplatin—esophageal cancer	0.000147	0.00511	CcSEcCtD
Capecitabine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000141	0.0049	CcSEcCtD
Capecitabine—Hyponatraemia—Cisplatin—esophageal cancer	0.000138	0.00482	CcSEcCtD
Capecitabine—Herpes zoster—Methotrexate—esophageal cancer	0.000138	0.00482	CcSEcCtD
Capecitabine—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000138	0.0048	CcSEcCtD
Capecitabine—Pleural effusion—Methotrexate—esophageal cancer	0.000136	0.00474	CcSEcCtD
Capecitabine—Hepatotoxicity—Methotrexate—esophageal cancer	0.000135	0.0047	CcSEcCtD
Capecitabine—Fungal infection—Methotrexate—esophageal cancer	0.000135	0.0047	CcSEcCtD
Capecitabine—Skin ulcer—Methotrexate—esophageal cancer	0.000134	0.00466	CcSEcCtD
Capecitabine—Face oedema—Cisplatin—esophageal cancer	0.000133	0.00463	CcSEcCtD
Capecitabine—Irritability—Cisplatin—esophageal cancer	0.000131	0.00458	CcSEcCtD
Capecitabine—Blood creatinine increased—Cisplatin—esophageal cancer	0.000129	0.00449	CcSEcCtD
Capecitabine—Dehydration—Cisplatin—esophageal cancer	0.000128	0.00446	CcSEcCtD
Capecitabine—Petechiae—Methotrexate—esophageal cancer	0.000127	0.00441	CcSEcCtD
Capecitabine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000126	0.00438	CcSEcCtD
Capecitabine—Hypokalaemia—Cisplatin—esophageal cancer	0.000125	0.00437	CcSEcCtD
Capecitabine—Breast disorder—Cisplatin—esophageal cancer	0.000124	0.00433	CcSEcCtD
Capecitabine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000124	0.00432	CcSEcCtD
Capecitabine—Nasopharyngitis—Cisplatin—esophageal cancer	0.000123	0.00429	CcSEcCtD
Capecitabine—Proteinuria—Methotrexate—esophageal cancer	0.000118	0.00413	CcSEcCtD
Capecitabine—Protein urine present—Methotrexate—esophageal cancer	0.000117	0.00407	CcSEcCtD
Capecitabine—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.000116	0.00404	CcSEcCtD
Capecitabine—Sweating increased—Cisplatin—esophageal cancer	0.000116	0.00404	CcSEcCtD
Capecitabine—Skin discolouration—Methotrexate—esophageal cancer	0.000115	0.00401	CcSEcCtD
Capecitabine—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000114	0.00399	CcSEcCtD
Capecitabine—Abdominal discomfort—Cisplatin—esophageal cancer	0.000114	0.00397	CcSEcCtD
Capecitabine—Pancytopenia—Cisplatin—esophageal cancer	0.000113	0.00394	CcSEcCtD
Capecitabine—Herpes simplex—Methotrexate—esophageal cancer	0.000113	0.00393	CcSEcCtD
Capecitabine—Ulcer—Methotrexate—esophageal cancer	0.00011	0.00383	CcSEcCtD
Capecitabine—Dysarthria—Methotrexate—esophageal cancer	0.00011	0.00383	CcSEcCtD
Capecitabine—Inflammation—Methotrexate—esophageal cancer	0.000107	0.00374	CcSEcCtD
Capecitabine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000105	0.00364	CcSEcCtD
Capecitabine—Renal failure—Cisplatin—esophageal cancer	0.000104	0.00363	CcSEcCtD
Capecitabine—Pulmonary embolism—Methotrexate—esophageal cancer	0.000104	0.00363	CcSEcCtD
Capecitabine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000104	0.00362	CcSEcCtD
Capecitabine—Myocardial infarction—Cisplatin—esophageal cancer	0.000104	0.00362	CcSEcCtD
Capecitabine—Stomatitis—Cisplatin—esophageal cancer	0.000103	0.0036	CcSEcCtD
Capecitabine—Conjunctivitis—Cisplatin—esophageal cancer	0.000103	0.00359	CcSEcCtD
Capecitabine—Melaena—Methotrexate—esophageal cancer	0.000102	0.00354	CcSEcCtD
Capecitabine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000101	0.0035	CcSEcCtD
Capecitabine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0001	0.0035	CcSEcCtD
Capecitabine—Skin exfoliation—Methotrexate—esophageal cancer	9.94e-05	0.00346	CcSEcCtD
Capecitabine—Bradycardia—Cisplatin—esophageal cancer	9.7e-05	0.00338	CcSEcCtD
Capecitabine—Mouth ulceration—Methotrexate—esophageal cancer	9.41e-05	0.00328	CcSEcCtD
Capecitabine—Ecchymosis—Methotrexate—esophageal cancer	9.41e-05	0.00328	CcSEcCtD
Capecitabine—Urine output increased—Methotrexate—esophageal cancer	9.41e-05	0.00328	CcSEcCtD
Capecitabine—Neoplasm—Methotrexate—esophageal cancer	9.41e-05	0.00328	CcSEcCtD
Capecitabine—Urinary tract disorder—Cisplatin—esophageal cancer	9.41e-05	0.00328	CcSEcCtD
Capecitabine—Connective tissue disorder—Cisplatin—esophageal cancer	9.36e-05	0.00326	CcSEcCtD
Capecitabine—Urethral disorder—Cisplatin—esophageal cancer	9.34e-05	0.00325	CcSEcCtD
Capecitabine—Visual impairment—Cisplatin—esophageal cancer	9.18e-05	0.0032	CcSEcCtD
Capecitabine—Sepsis—Methotrexate—esophageal cancer	9.03e-05	0.00315	CcSEcCtD
Capecitabine—Eye disorder—Cisplatin—esophageal cancer	8.9e-05	0.0031	CcSEcCtD
Capecitabine—Tinnitus—Cisplatin—esophageal cancer	8.88e-05	0.00309	CcSEcCtD
Capecitabine—Flushing—Cisplatin—esophageal cancer	8.84e-05	0.00308	CcSEcCtD
Capecitabine—Cardiac disorder—Cisplatin—esophageal cancer	8.84e-05	0.00308	CcSEcCtD
Capecitabine—Thrombophlebitis—Methotrexate—esophageal cancer	8.73e-05	0.00304	CcSEcCtD
Capecitabine—Diabetes mellitus—Methotrexate—esophageal cancer	8.69e-05	0.00303	CcSEcCtD
Capecitabine—Photosensitivity—Methotrexate—esophageal cancer	8.61e-05	0.003	CcSEcCtD
Capecitabine—Polyuria—Methotrexate—esophageal cancer	8.61e-05	0.003	CcSEcCtD
Capecitabine—Immune system disorder—Cisplatin—esophageal cancer	8.6e-05	0.003	CcSEcCtD
Capecitabine—Mediastinal disorder—Cisplatin—esophageal cancer	8.59e-05	0.00299	CcSEcCtD
Capecitabine—Arrhythmia—Cisplatin—esophageal cancer	8.51e-05	0.00296	CcSEcCtD
Capecitabine—Alopecia—Cisplatin—esophageal cancer	8.42e-05	0.00293	CcSEcCtD
Capecitabine—Hepatic failure—Methotrexate—esophageal cancer	8.41e-05	0.00293	CcSEcCtD
Capecitabine—Erythema—Cisplatin—esophageal cancer	8.29e-05	0.00289	CcSEcCtD
Capecitabine—Malnutrition—Cisplatin—esophageal cancer	8.29e-05	0.00289	CcSEcCtD
Capecitabine—Renal failure acute—Methotrexate—esophageal cancer	8.18e-05	0.00285	CcSEcCtD
Capecitabine—Flatulence—Cisplatin—esophageal cancer	8.17e-05	0.00285	CcSEcCtD
Capecitabine—Dermatitis exfoliative—Methotrexate—esophageal cancer	8.01e-05	0.00279	CcSEcCtD
Capecitabine—Muscle spasms—Cisplatin—esophageal cancer	7.97e-05	0.00278	CcSEcCtD
Capecitabine—CES1—E2F transcription factor network—MYC—esophageal cancer	7.83e-05	0.00146	CbGpPWpGaD
Capecitabine—Vision blurred—Cisplatin—esophageal cancer	7.82e-05	0.00272	CcSEcCtD
Capecitabine—Tremor—Cisplatin—esophageal cancer	7.77e-05	0.00271	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	7.73e-05	0.00144	CbGpPWpGaD
Capecitabine—Cerebrovascular accident—Methotrexate—esophageal cancer	7.71e-05	0.00269	CcSEcCtD
Capecitabine—Lethargy—Methotrexate—esophageal cancer	7.71e-05	0.00269	CcSEcCtD
Capecitabine—Ill-defined disorder—Cisplatin—esophageal cancer	7.69e-05	0.00268	CcSEcCtD
Capecitabine—Anaemia—Cisplatin—esophageal cancer	7.66e-05	0.00267	CcSEcCtD
Capecitabine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	7.64e-05	0.00143	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	7.63e-05	0.00142	CbGpPWpGaD
Capecitabine—Osteoarthritis—Methotrexate—esophageal cancer	7.56e-05	0.00263	CcSEcCtD
Capecitabine—CDA—Metabolism—ADH7—esophageal cancer	7.49e-05	0.0014	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PLCE1—esophageal cancer	7.49e-05	0.0014	CbGpPWpGaD
Capecitabine—Malaise—Cisplatin—esophageal cancer	7.48e-05	0.00261	CcSEcCtD
Capecitabine—Leukopenia—Cisplatin—esophageal cancer	7.42e-05	0.00259	CcSEcCtD
Capecitabine—DPYD—Metabolism—ADH1B—esophageal cancer	7.36e-05	0.00137	CbGpPWpGaD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	7.28e-05	0.00136	CbGpPWpGaD
Capecitabine—Irritability—Methotrexate—esophageal cancer	7.21e-05	0.00251	CcSEcCtD
Capecitabine—Mood swings—Methotrexate—esophageal cancer	7.16e-05	0.00249	CcSEcCtD
Capecitabine—Ataxia—Methotrexate—esophageal cancer	7.11e-05	0.00248	CcSEcCtD
Capecitabine—Myalgia—Cisplatin—esophageal cancer	7.06e-05	0.00246	CcSEcCtD
Capecitabine—DPYD—Metabolism—TYMP—esophageal cancer	7.04e-05	0.00131	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CA1—esophageal cancer	7.04e-05	0.00131	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—SLC10A2—esophageal cancer	7.04e-05	0.00131	CbGpPWpGaD
Capecitabine—Anxiety—Cisplatin—esophageal cancer	7.04e-05	0.00245	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	7.01e-05	0.00244	CcSEcCtD
Capecitabine—Liver function test abnormal—Methotrexate—esophageal cancer	6.98e-05	0.00243	CcSEcCtD
Capecitabine—Discomfort—Cisplatin—esophageal cancer	6.98e-05	0.00243	CcSEcCtD
Capecitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	6.96e-05	0.0013	CbGpPWpGaD
Capecitabine—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	6.87e-05	0.00128	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CYP26A1—esophageal cancer	6.85e-05	0.00128	CbGpPWpGaD
Capecitabine—Breast disorder—Methotrexate—esophageal cancer	6.83e-05	0.00238	CcSEcCtD
Capecitabine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	6.8e-05	0.00237	CcSEcCtD
Capecitabine—Oedema—Cisplatin—esophageal cancer	6.77e-05	0.00236	CcSEcCtD
Capecitabine—Infection—Cisplatin—esophageal cancer	6.72e-05	0.00234	CcSEcCtD
Capecitabine—DPYD—Metabolism—ALOX15—esophageal cancer	6.67e-05	0.00125	CbGpPWpGaD
Capecitabine—Nervous system disorder—Cisplatin—esophageal cancer	6.64e-05	0.00231	CcSEcCtD
Capecitabine—Thrombocytopenia—Cisplatin—esophageal cancer	6.63e-05	0.00231	CcSEcCtD
Capecitabine—TYMS—G1/S Transition—RB1—esophageal cancer	6.62e-05	0.00124	CbGpPWpGaD
Capecitabine—Tachycardia—Cisplatin—esophageal cancer	6.61e-05	0.0023	CcSEcCtD
Capecitabine—Skin disorder—Cisplatin—esophageal cancer	6.57e-05	0.00229	CcSEcCtD
Capecitabine—CDA—Metabolism—ADH1B—esophageal cancer	6.56e-05	0.00122	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—CDKN1A—esophageal cancer	6.55e-05	0.00122	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	6.55e-05	0.00122	CbGpPWpGaD
Capecitabine—Hyperhidrosis—Cisplatin—esophageal cancer	6.54e-05	0.00228	CcSEcCtD
Capecitabine—Asthma—Methotrexate—esophageal cancer	6.53e-05	0.00228	CcSEcCtD
Capecitabine—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	6.49e-05	0.00121	CbGpPWpGaD
Capecitabine—Anorexia—Cisplatin—esophageal cancer	6.45e-05	0.00225	CcSEcCtD
Capecitabine—TYMP—Metabolism—CA2—esophageal cancer	6.44e-05	0.0012	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTO1—esophageal cancer	6.36e-05	0.00119	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—TPI1—esophageal cancer	6.36e-05	0.00119	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.35e-05	0.00118	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	6.35e-05	0.00118	CbGpPWpGaD
Capecitabine—Hypotension—Cisplatin—esophageal cancer	6.32e-05	0.0022	CcSEcCtD
Capecitabine—CDA—Metabolism—TYMP—esophageal cancer	6.27e-05	0.00117	CbGpPWpGaD
Capecitabine—Abdominal discomfort—Methotrexate—esophageal cancer	6.26e-05	0.00218	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—EP300—esophageal cancer	6.24e-05	0.00116	CbGpPWpGaD
Capecitabine—Pancytopenia—Methotrexate—esophageal cancer	6.2e-05	0.00216	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	6.17e-05	0.00215	CcSEcCtD
Capecitabine—Dysuria—Methotrexate—esophageal cancer	6.11e-05	0.00213	CcSEcCtD
Capecitabine—Neutropenia—Methotrexate—esophageal cancer	6.11e-05	0.00213	CcSEcCtD
Capecitabine—CDA—Metabolism—CYP26A1—esophageal cancer	6.1e-05	0.00114	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ALDOB—esophageal cancer	6.1e-05	0.00114	CbGpPWpGaD
Capecitabine—Paraesthesia—Cisplatin—esophageal cancer	6.08e-05	0.00212	CcSEcCtD
Capecitabine—Upper respiratory tract infection—Methotrexate—esophageal cancer	6.07e-05	0.00211	CcSEcCtD
Capecitabine—Dyspnoea—Cisplatin—esophageal cancer	6.03e-05	0.0021	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6e-05	0.00112	CbGpPWpGaD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	6e-05	0.00112	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PLCE1—esophageal cancer	5.98e-05	0.00112	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ADH7—esophageal cancer	5.98e-05	0.00112	CbGpPWpGaD
Capecitabine—Photosensitivity reaction—Methotrexate—esophageal cancer	5.96e-05	0.00208	CcSEcCtD
Capecitabine—CDA—Metabolism—ALOX15—esophageal cancer	5.95e-05	0.00111	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	5.89e-05	0.0011	CbGpPWpGaD
Capecitabine—Decreased appetite—Cisplatin—esophageal cancer	5.88e-05	0.00205	CcSEcCtD
Capecitabine—DPYD—Metabolism—GAPDH—esophageal cancer	5.87e-05	0.0011	CbGpPWpGaD
Capecitabine—Pneumonia—Methotrexate—esophageal cancer	5.86e-05	0.00204	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Cisplatin—esophageal cancer	5.84e-05	0.00204	CcSEcCtD
Capecitabine—Infestation—Methotrexate—esophageal cancer	5.82e-05	0.00203	CcSEcCtD
Capecitabine—Infestation NOS—Methotrexate—esophageal cancer	5.82e-05	0.00203	CcSEcCtD
Capecitabine—DPYD—Metabolism—CRABP1—esophageal cancer	5.82e-05	0.00109	CbGpPWpGaD
Capecitabine—Depression—Methotrexate—esophageal cancer	5.81e-05	0.00202	CcSEcCtD
Capecitabine—Pain—Cisplatin—esophageal cancer	5.79e-05	0.00202	CcSEcCtD
Capecitabine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	5.77e-05	0.00201	CcSEcCtD
Capecitabine—Renal failure—Methotrexate—esophageal cancer	5.72e-05	0.00199	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	5.7e-05	0.00106	CbGpPWpGaD
Capecitabine—Stomatitis—Methotrexate—esophageal cancer	5.68e-05	0.00198	CcSEcCtD
Capecitabine—CDA—Metabolism—GSTO1—esophageal cancer	5.67e-05	0.00106	CbGpPWpGaD
Capecitabine—CDA—Metabolism—TPI1—esophageal cancer	5.67e-05	0.00106	CbGpPWpGaD
Capecitabine—Conjunctivitis—Methotrexate—esophageal cancer	5.66e-05	0.00197	CcSEcCtD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	5.64e-05	0.00105	CbGpPWpGaD
Capecitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	5.61e-05	0.00105	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—RB1—esophageal cancer	5.58e-05	0.00104	CbGpPWpGaD
Capecitabine—Feeling abnormal—Cisplatin—esophageal cancer	5.58e-05	0.00194	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	5.57e-05	0.00104	CbGpPWpGaD
Capecitabine—Haematuria—Methotrexate—esophageal cancer	5.55e-05	0.00193	CcSEcCtD
Capecitabine—DPYD—Metabolism—GNG7—esophageal cancer	5.54e-05	0.00103	CbGpPWpGaD
Capecitabine—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	5.54e-05	0.00103	CbGpPWpGaD
Capecitabine—Hepatobiliary disease—Methotrexate—esophageal cancer	5.51e-05	0.00192	CcSEcCtD
Capecitabine—Epistaxis—Methotrexate—esophageal cancer	5.49e-05	0.00191	CcSEcCtD
Capecitabine—CDA—Metabolism—ALDOB—esophageal cancer	5.44e-05	0.00101	CbGpPWpGaD
Capecitabine—Agranulocytosis—Methotrexate—esophageal cancer	5.43e-05	0.00189	CcSEcCtD
Capecitabine—TYMS—E2F transcription factor network—MYC—esophageal cancer	5.43e-05	0.00101	CbGpPWpGaD
Capecitabine—Body temperature increased—Cisplatin—esophageal cancer	5.35e-05	0.00186	CcSEcCtD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	5.35e-05	0.000998	CbGpPWpGaD
Capecitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	5.27e-05	0.000984	CbGpPWpGaD
Capecitabine—Haemoglobin—Methotrexate—esophageal cancer	5.25e-05	0.00183	CcSEcCtD
Capecitabine—TYMP—Metabolism—ADH1B—esophageal cancer	5.25e-05	0.000979	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GAPDH—esophageal cancer	5.24e-05	0.000977	CbGpPWpGaD
Capecitabine—Hepatitis—Methotrexate—esophageal cancer	5.23e-05	0.00182	CcSEcCtD
Capecitabine—Haemorrhage—Methotrexate—esophageal cancer	5.23e-05	0.00182	CcSEcCtD
Capecitabine—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	5.21e-05	0.000971	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CRABP1—esophageal cancer	5.19e-05	0.000968	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ALDH2—esophageal cancer	5.19e-05	0.000968	CbGpPWpGaD
Capecitabine—Pharyngitis—Methotrexate—esophageal cancer	5.19e-05	0.00181	CcSEcCtD
Capecitabine—Urinary tract disorder—Methotrexate—esophageal cancer	5.16e-05	0.0018	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—ADH7—esophageal cancer	5.16e-05	0.000963	CbGpPWpGaD
Capecitabine—Urethral disorder—Methotrexate—esophageal cancer	5.12e-05	0.00179	CcSEcCtD
Capecitabine—Visual impairment—Methotrexate—esophageal cancer	5.04e-05	0.00175	CcSEcCtD
Capecitabine—Hypersensitivity—Cisplatin—esophageal cancer	4.99e-05	0.00174	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—HIST1H2BM—esophageal cancer	4.98e-05	0.00093	CbGpPWpGaD
Capecitabine—Erythema multiforme—Methotrexate—esophageal cancer	4.94e-05	0.00172	CcSEcCtD
Capecitabine—CDA—Metabolism—GNG7—esophageal cancer	4.94e-05	0.000921	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTT1—esophageal cancer	4.94e-05	0.000921	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	4.92e-05	0.000919	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	4.9e-05	0.000915	CbGpPWpGaD
Capecitabine—Eye disorder—Methotrexate—esophageal cancer	4.89e-05	0.0017	CcSEcCtD
Capecitabine—DPYD—Metabolism—CYP2A6—esophageal cancer	4.88e-05	0.00091	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CYP26A1—esophageal cancer	4.88e-05	0.00091	CbGpPWpGaD
Capecitabine—Tinnitus—Methotrexate—esophageal cancer	4.87e-05	0.0017	CcSEcCtD
Capecitabine—Asthenia—Cisplatin—esophageal cancer	4.86e-05	0.00169	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—esophageal cancer	4.85e-05	0.00169	CcSEcCtD
Capecitabine—TYMS—G1/S Transition—CDKN1A—esophageal cancer	4.76e-05	0.000887	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ALOX15—esophageal cancer	4.75e-05	0.000887	CbGpPWpGaD
Capecitabine—Angiopathy—Methotrexate—esophageal cancer	4.74e-05	0.00165	CcSEcCtD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	4.72e-05	0.000881	CbGpPWpGaD
Capecitabine—Immune system disorder—Methotrexate—esophageal cancer	4.72e-05	0.00164	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—esophageal cancer	4.71e-05	0.00164	CcSEcCtD
Capecitabine—Chills—Methotrexate—esophageal cancer	4.69e-05	0.00163	CcSEcCtD
Capecitabine—Diarrhoea—Cisplatin—esophageal cancer	4.63e-05	0.00161	CcSEcCtD
Capecitabine—DPYD—Metabolism—ENO1—esophageal cancer	4.62e-05	0.000863	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PTGS1—esophageal cancer	4.62e-05	0.000863	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ALDH2—esophageal cancer	4.62e-05	0.000863	CbGpPWpGaD
Capecitabine—Alopecia—Methotrexate—esophageal cancer	4.62e-05	0.00161	CcSEcCtD
Capecitabine—Mental disorder—Methotrexate—esophageal cancer	4.58e-05	0.0016	CcSEcCtD
Capecitabine—DPYD—Metabolism—PSME1—esophageal cancer	4.56e-05	0.00085	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PSME2—esophageal cancer	4.56e-05	0.00085	CbGpPWpGaD
Capecitabine—Malnutrition—Methotrexate—esophageal cancer	4.55e-05	0.00159	CcSEcCtD
Capecitabine—Erythema—Methotrexate—esophageal cancer	4.55e-05	0.00159	CcSEcCtD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	4.55e-05	0.000849	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTO1—esophageal cancer	4.54e-05	0.000846	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—TPI1—esophageal cancer	4.54e-05	0.000846	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—NOS2—esophageal cancer	4.53e-05	0.000846	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	4.52e-05	0.000844	CbGpPWpGaD
Capecitabine—Dysgeusia—Methotrexate—esophageal cancer	4.46e-05	0.00155	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—MAD2L1—esophageal cancer	4.4e-05	0.000821	CbGpPWpGaD
Capecitabine—Back pain—Methotrexate—esophageal cancer	4.4e-05	0.00153	CcSEcCtD
Capecitabine—CDA—Metabolism—GSTT1—esophageal cancer	4.4e-05	0.000821	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CYP2A6—esophageal cancer	4.35e-05	0.000811	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ALDOB—esophageal cancer	4.35e-05	0.000811	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—PSME2—esophageal cancer	4.32e-05	0.000807	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—PSME1—esophageal cancer	4.32e-05	0.000807	CbGpPWpGaD
Capecitabine—Vomiting—Cisplatin—esophageal cancer	4.3e-05	0.0015	CcSEcCtD
Capecitabine—Vision blurred—Methotrexate—esophageal cancer	4.29e-05	0.00149	CcSEcCtD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	4.28e-05	0.000798	CbGpPWpGaD
Capecitabine—Rash—Cisplatin—esophageal cancer	4.27e-05	0.00149	CcSEcCtD
Capecitabine—Dermatitis—Cisplatin—esophageal cancer	4.26e-05	0.00149	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.26e-05	0.000795	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.24e-05	0.000792	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SLC52A3—esophageal cancer	4.23e-05	0.00079	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—BLVRB—esophageal cancer	4.23e-05	0.00079	CbGpPWpGaD
Capecitabine—Ill-defined disorder—Methotrexate—esophageal cancer	4.22e-05	0.00147	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	4.21e-05	0.000785	CbGpPWpGaD
Capecitabine—Anaemia—Methotrexate—esophageal cancer	4.21e-05	0.00147	CcSEcCtD
Capecitabine—TYMP—Metabolism—GAPDH—esophageal cancer	4.19e-05	0.000781	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	4.15e-05	0.000774	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CRABP1—esophageal cancer	4.15e-05	0.000774	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CCND1—esophageal cancer	4.14e-05	0.000773	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTGS1—esophageal cancer	4.12e-05	0.000769	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ENO1—esophageal cancer	4.12e-05	0.000769	CbGpPWpGaD
Capecitabine—Malaise—Methotrexate—esophageal cancer	4.1e-05	0.00143	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—esophageal cancer	4.09e-05	0.00142	CcSEcCtD
Capecitabine—Leukopenia—Methotrexate—esophageal cancer	4.07e-05	0.00142	CcSEcCtD
Capecitabine—CDA—Metabolism—PSME2—esophageal cancer	4.06e-05	0.000758	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PSME1—esophageal cancer	4.06e-05	0.000758	CbGpPWpGaD
Capecitabine—Nausea—Cisplatin—esophageal cancer	4.02e-05	0.0014	CcSEcCtD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	4.01e-05	0.000748	CbGpPWpGaD
Capecitabine—Cough—Methotrexate—esophageal cancer	3.97e-05	0.00138	CcSEcCtD
Capecitabine—TYMP—Metabolism—GNG7—esophageal cancer	3.95e-05	0.000736	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—MYC—esophageal cancer	3.94e-05	0.000736	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—BUB1B—esophageal cancer	3.94e-05	0.000734	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CYP1B1—esophageal cancer	3.93e-05	0.000734	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	3.91e-05	0.00073	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	3.88e-05	0.000724	CbGpPWpGaD
Capecitabine—Myalgia—Methotrexate—esophageal cancer	3.87e-05	0.00135	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—esophageal cancer	3.87e-05	0.00135	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—esophageal cancer	3.87e-05	0.00135	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—PSME2—esophageal cancer	3.87e-05	0.000721	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—PSME1—esophageal cancer	3.87e-05	0.000721	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	3.86e-05	0.00072	CbGpPWpGaD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	3.85e-05	0.00134	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—esophageal cancer	3.83e-05	0.00133	CcSEcCtD
Capecitabine—Confusional state—Methotrexate—esophageal cancer	3.74e-05	0.0013	CcSEcCtD
Capecitabine—DPYD—Metabolism—CYP19A1—esophageal cancer	3.7e-05	0.00069	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ALDH2—esophageal cancer	3.7e-05	0.00069	CbGpPWpGaD
Capecitabine—Infection—Methotrexate—esophageal cancer	3.69e-05	0.00129	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.66e-05	0.000682	CbGpPWpGaD
Capecitabine—Nervous system disorder—Methotrexate—esophageal cancer	3.64e-05	0.00127	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—esophageal cancer	3.64e-05	0.00127	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—esophageal cancer	3.61e-05	0.00126	CcSEcCtD
Capecitabine—TYMS—Metabolism—CA1—esophageal cancer	3.6e-05	0.000672	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SLC10A2—esophageal cancer	3.6e-05	0.000672	CbGpPWpGaD
Capecitabine—Hyperhidrosis—Methotrexate—esophageal cancer	3.59e-05	0.00125	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.55e-05	0.000663	CbGpPWpGaD
Capecitabine—Anorexia—Methotrexate—esophageal cancer	3.54e-05	0.00123	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—BUB1B—esophageal cancer	3.52e-05	0.000657	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTT1—esophageal cancer	3.52e-05	0.000656	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CYP1B1—esophageal cancer	3.5e-05	0.000654	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CYP2A6—esophageal cancer	3.48e-05	0.000649	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.47e-05	0.000648	CbGpPWpGaD
Capecitabine—Hypotension—Methotrexate—esophageal cancer	3.47e-05	0.00121	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	3.38e-05	0.00118	CcSEcCtD
Capecitabine—DPYD—Metabolism—HMOX1—esophageal cancer	3.37e-05	0.00063	CbGpPWpGaD
Capecitabine—Insomnia—Methotrexate—esophageal cancer	3.36e-05	0.00117	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CHEK2—esophageal cancer	3.35e-05	0.000625	CbGpPWpGaD
Capecitabine—Paraesthesia—Methotrexate—esophageal cancer	3.33e-05	0.00116	CcSEcCtD
Capecitabine—TYMS—Mitotic G1-G1/S phases—MYC—esophageal cancer	3.32e-05	0.00062	CbGpPWpGaD
Capecitabine—Dyspnoea—Methotrexate—esophageal cancer	3.31e-05	0.00115	CcSEcCtD
Capecitabine—CDA—Metabolism—CYP19A1—esophageal cancer	3.3e-05	0.000615	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTGS1—esophageal cancer	3.3e-05	0.000615	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ENO1—esophageal cancer	3.3e-05	0.000615	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CA2—esophageal cancer	3.29e-05	0.000614	CbGpPWpGaD
Capecitabine—Dyspepsia—Methotrexate—esophageal cancer	3.27e-05	0.00114	CcSEcCtD
Capecitabine—TYMP—Metabolism—PSME2—esophageal cancer	3.25e-05	0.000606	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PSME1—esophageal cancer	3.25e-05	0.000606	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ABCB1—esophageal cancer	3.24e-05	0.000604	CbGpPWpGaD
Capecitabine—Decreased appetite—Methotrexate—esophageal cancer	3.23e-05	0.00112	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Methotrexate—esophageal cancer	3.21e-05	0.00112	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—esophageal cancer	3.2e-05	0.00112	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	3.19e-05	0.000595	CbGpPWpGaD
Capecitabine—Pain—Methotrexate—esophageal cancer	3.18e-05	0.00111	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.14e-05	0.000586	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PLCE1—esophageal cancer	3.06e-05	0.000571	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ADH7—esophageal cancer	3.06e-05	0.000571	CbGpPWpGaD
Capecitabine—Feeling abnormal—Methotrexate—esophageal cancer	3.06e-05	0.00107	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—esophageal cancer	3.04e-05	0.00106	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.04e-05	0.000567	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	3.03e-05	0.000566	CbGpPWpGaD
Capecitabine—CDA—Metabolism—HMOX1—esophageal cancer	3.01e-05	0.000561	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	3e-05	0.000559	CbGpPWpGaD
Capecitabine—Urticaria—Methotrexate—esophageal cancer	2.95e-05	0.00103	CcSEcCtD
Capecitabine—Body temperature increased—Methotrexate—esophageal cancer	2.94e-05	0.00102	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—esophageal cancer	2.94e-05	0.00102	CcSEcCtD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	2.93e-05	0.000546	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.89e-05	0.000539	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ABCB1—esophageal cancer	2.89e-05	0.000539	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	2.84e-05	0.00053	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CYP1B1—esophageal cancer	2.8e-05	0.000523	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—EP300—esophageal cancer	2.77e-05	0.000518	CbGpPWpGaD
Capecitabine—Hypersensitivity—Methotrexate—esophageal cancer	2.74e-05	0.000953	CcSEcCtD
Capecitabine—TYMS—Metabolism—ADH1B—esophageal cancer	2.68e-05	0.000501	CbGpPWpGaD
Capecitabine—Asthenia—Methotrexate—esophageal cancer	2.66e-05	0.000928	CcSEcCtD
Capecitabine—TYMP—Metabolism—CYP19A1—esophageal cancer	2.63e-05	0.000492	CbGpPWpGaD
Capecitabine—Pruritus—Methotrexate—esophageal cancer	2.63e-05	0.000915	CcSEcCtD
Capecitabine—TYMS—Metabolism—TYMP—esophageal cancer	2.57e-05	0.000479	CbGpPWpGaD
Capecitabine—Diarrhoea—Methotrexate—esophageal cancer	2.54e-05	0.000885	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.52e-05	0.00047	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP26A1—esophageal cancer	2.5e-05	0.000466	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.46e-05	0.000459	CbGpPWpGaD
Capecitabine—Dizziness—Methotrexate—esophageal cancer	2.46e-05	0.000856	CcSEcCtD
Capecitabine—TYMS—Metabolism—ALOX15—esophageal cancer	2.43e-05	0.000454	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	2.42e-05	0.000451	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—HMOX1—esophageal cancer	2.4e-05	0.000449	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	2.38e-05	0.000445	CbGpPWpGaD
Capecitabine—Vomiting—Methotrexate—esophageal cancer	2.36e-05	0.000823	CcSEcCtD
Capecitabine—Rash—Methotrexate—esophageal cancer	2.34e-05	0.000816	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—esophageal cancer	2.34e-05	0.000815	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	2.33e-05	0.000435	CbGpPWpGaD
Capecitabine—Headache—Methotrexate—esophageal cancer	2.33e-05	0.00081	CcSEcCtD
Capecitabine—TYMS—Metabolism—GSTO1—esophageal cancer	2.32e-05	0.000433	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—TPI1—esophageal cancer	2.32e-05	0.000433	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ABCB1—esophageal cancer	2.31e-05	0.000431	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	2.27e-05	0.000424	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	2.24e-05	0.000418	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ALDOB—esophageal cancer	2.22e-05	0.000415	CbGpPWpGaD
Capecitabine—Nausea—Methotrexate—esophageal cancer	2.21e-05	0.000768	CcSEcCtD
Capecitabine—DPYD—Metabolism—CREBBP—esophageal cancer	2.16e-05	0.000404	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GAPDH—esophageal cancer	2.14e-05	0.0004	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.14e-05	0.000399	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CRABP1—esophageal cancer	2.12e-05	0.000396	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.07e-05	0.000386	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—RB1—esophageal cancer	2.05e-05	0.000382	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GNG7—esophageal cancer	2.02e-05	0.000377	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—TP53—esophageal cancer	1.98e-05	0.00037	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NOS3—esophageal cancer	1.94e-05	0.000362	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CREBBP—esophageal cancer	1.93e-05	0.00036	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ALDH2—esophageal cancer	1.89e-05	0.000353	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—RB1—esophageal cancer	1.83e-05	0.000341	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTT1—esophageal cancer	1.8e-05	0.000336	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	1.8e-05	0.000336	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP2A6—esophageal cancer	1.78e-05	0.000332	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PTGS2—esophageal cancer	1.77e-05	0.000331	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NOS3—esophageal cancer	1.73e-05	0.000322	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ENO1—esophageal cancer	1.69e-05	0.000315	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS1—esophageal cancer	1.69e-05	0.000315	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PSME2—esophageal cancer	1.66e-05	0.00031	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PSME1—esophageal cancer	1.66e-05	0.00031	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CDKN2A—esophageal cancer	1.61e-05	0.0003	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTGS2—esophageal cancer	1.58e-05	0.000295	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	1.57e-05	0.000294	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CREBBP—esophageal cancer	1.54e-05	0.000288	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.52e-05	0.000284	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—EP300—esophageal cancer	1.47e-05	0.000275	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.47e-05	0.000274	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP1B1—esophageal cancer	1.43e-05	0.000267	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—EP300—esophageal cancer	1.4e-05	0.000261	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NOS3—esophageal cancer	1.38e-05	0.000258	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	1.37e-05	0.000256	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CCND1—esophageal cancer	1.36e-05	0.000254	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP19A1—esophageal cancer	1.35e-05	0.000251	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CDKN1A—esophageal cancer	1.31e-05	0.000245	CbGpPWpGaD
Capecitabine—CDA—Metabolism—EP300—esophageal cancer	1.31e-05	0.000245	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTGS2—esophageal cancer	1.26e-05	0.000236	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—EP300—esophageal cancer	1.25e-05	0.000233	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—HMOX1—esophageal cancer	1.23e-05	0.000229	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—BLVRB—esophageal cancer	1.22e-05	0.000228	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SLC52A3—esophageal cancer	1.22e-05	0.000228	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—MYC—esophageal cancer	1.22e-05	0.000227	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ABCB1—esophageal cancer	1.18e-05	0.00022	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.09e-05	0.000204	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PIK3CA—esophageal cancer	1.09e-05	0.000203	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MYC—esophageal cancer	1.09e-05	0.000203	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—EP300—esophageal cancer	1.05e-05	0.000196	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SLC10A2—esophageal cancer	1.04e-05	0.000194	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CA1—esophageal cancer	1.04e-05	0.000194	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PIK3CA—esophageal cancer	9.72e-06	0.000181	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CA2—esophageal cancer	9.49e-06	0.000177	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.28e-06	0.000173	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—esophageal cancer	8.95e-06	0.000167	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PLCE1—esophageal cancer	8.82e-06	0.000165	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ADH7—esophageal cancer	8.82e-06	0.000165	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.72e-06	0.000163	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CREBBP—esophageal cancer	7.89e-06	0.000147	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PIK3CA—esophageal cancer	7.77e-06	0.000145	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ADH1B—esophageal cancer	7.74e-06	0.000144	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TYMP—esophageal cancer	7.39e-06	0.000138	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	7.19e-06	0.000134	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NOS3—esophageal cancer	7.06e-06	0.000132	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ALOX15—esophageal cancer	7.01e-06	0.000131	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTO1—esophageal cancer	6.69e-06	0.000125	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TPI1—esophageal cancer	6.69e-06	0.000125	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—esophageal cancer	6.46e-06	0.000121	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ALDOB—esophageal cancer	6.41e-06	0.00012	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GAPDH—esophageal cancer	6.17e-06	0.000115	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CRABP1—esophageal cancer	6.12e-06	0.000114	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GNG7—esophageal cancer	5.82e-06	0.000109	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ALDH2—esophageal cancer	5.45e-06	0.000102	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—EP300—esophageal cancer	5.37e-06	0.0001	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTT1—esophageal cancer	5.19e-06	9.68e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	5.13e-06	9.56e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.11e-06	9.53e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS1—esophageal cancer	4.86e-06	9.07e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ENO1—esophageal cancer	4.86e-06	9.07e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PSME2—esophageal cancer	4.79e-06	8.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PSME1—esophageal cancer	4.79e-06	8.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.18e-06	7.8e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	4.13e-06	7.71e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CA—esophageal cancer	3.97e-06	7.42e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	3.88e-06	7.25e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.54e-06	6.61e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.48e-06	6.49e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.4e-06	6.35e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.57e-06	4.8e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.27e-06	4.24e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NOS3—esophageal cancer	2.04e-06	3.8e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.86e-06	3.47e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—EP300—esophageal cancer	1.55e-06	2.89e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.15e-06	2.14e-05	CbGpPWpGaD
